Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine

BACKGROUND: The treatment of ulcerative colitis (UC) can place a substantial financial burden on healthcare systems. The anti-inflammatory compound 5-aminosalicylic acid (5-ASA; mesalazine) is the recommended first-line treatment for patients with UC. In this analysis, the incremental cost effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Prenzler, Anne, Yen, Linnette, Mittendorf, Thomas, von der Schulenburg, J-Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146407/
https://www.ncbi.nlm.nih.gov/pubmed/21729262
http://dx.doi.org/10.1186/1472-6963-11-157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146407/
https://www.ncbi.nlm.nih.gov/pubmed/21729262
http://dx.doi.org/10.1186/1472-6963-11-157

Ejemplares similares